¼¼°èÀÇ ±âµµ/Æó ½ºÅÙÆ® ½ÃÀå
Airway/Lung Stents
»óǰÄÚµå : 1765365
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 194 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,171,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,515,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

±âµµ/Æó ½ºÅÙÆ® ¼¼°è ½ÃÀåÀº 2030³â±îÁö 1¾ï 6,380¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 1¾ï 1,930¸¸ ´Þ·¯·Î ÃßÁ¤µÇ´Â ±âµµ/Æó ½ºÅÙÆ® ¼¼°è ½ÃÀåÀº ºÐ¼® ±â°£ÀÎ 2024-2030³â¿¡ CAGR 5.4%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 1¾ï 6,380¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±â°üÀº CAGR 5.6%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 9,660¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÈĵΠºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 5.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 3,280¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.1%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±âµµ/Æó ½ºÅÙÆ® ½ÃÀåÀº 2024³â¿¡ 3,280¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 5.1%·Î 2030³â±îÁö 2,560¸¸ ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 5.1%¿Í 4.1%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ±âµµ/Æó ½ºÅÙÆ® ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

±âµµ/Æó ½ºÅÙÆ®´Â ¹«¾ùÀ̸ç, ¿Ö È£Èí±â Ä¡·á¿¡ ÇʼöÀûÀΰ¡?

±âµµ ½ºÅÙÆ® ¶Ç´Â Æó ½ºÅÙÆ®´Â ƯÈ÷ ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD), Æó¾Ï, ±â°üÁöÆó»ö°ú °°Àº ÁúȯÀ» ¾Î°í Àִ ȯÀÚ¿¡¼­ È£Èí±âÀÇ °³ÅëÀ» À¯ÁöÇϵµ·Ï ¼³°èµÈ Áß¿äÇÑ ÀÇ·á±â±âÀÔ´Ï´Ù. ±Ý¼ÓÀ̳ª ½Ç¸®Äܰú °°Àº Àç·á·Î ¸¸µé¾îÁø ÀÌ ½ºÅÙÆ®´Â ±âµµÀÇ ÇãÅ»À» ¹æÁöÇϰí ȯÀÚÀÇ È£ÈíÀ» ¿ëÀÌÇÏ°Ô Çϸç Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» Çâ»ó½ÃŰ´Â µ¥ »ç¿ëµË´Ï´Ù. ±âµµ ½ºÅÙÆ®´Â ¼ö¼ú¿¡ ÀûÇÕÇÏÁö ¾ÊÀº ȯÀÚ³ª ¾à¹° Ä¡·á¿Í °°Àº ±âÁ¸ Ä¡·á·Î ½É°¢ÇÑ È£Èí Æó¼â¿¡ ´ëóÇÒ ¼ö ¾ø´Â ȯÀڵ鿡°Ô ƯÈ÷ Áß¿äÇÕ´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î È£Èí±âÁúȯÀÇ ¹ßº´·üÀÌ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ȯÀÚ Ä¡·á¿¡¼­ ±âµµ ½ºÅÙÆ®ÀÇ ¿ªÇÒÀÌ ´õ¿í Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¾î¶»°Ô ±âµµ ½ºÅÙÆ® ¼³°è¿¡ Çõ¸íÀ» ÀÏÀ¸Å°°í Àִ°¡?

±â¼úÀÇ ¹ßÀüÀ¸·Î ±âµµ/Æó ½ºÅÙÆ®ÀÇ µðÀÚÀΰú ±â´ÉÀÌ Å©°Ô °³¼±µÇ¾ú½À´Ï´Ù. Á¦°Å°¡ ¿ëÀÌÇϰí À¯¿¬¼ºÀÌ ¶Ù¾î³µ´ø ±âÁ¸ÀÇ ½Ç¸®ÄÜ ½ºÅÙÆ®´Â ÇöÀç ¶Ù¾î³­ ³»±¸¼º°ú Àå±âÀûÀÎ ±¸Á¶Àû ÁöÁö·ÂÀ» Á¦°øÇÏ´Â ±Ý¼Ó ½ºÅÙÆ®·Î º¸¿ÏµÇ°í ÀÖ½À´Ï´Ù. ÃÖ±Ù¿¡´Â µÎ Àç·áÀÇ ÀåÁ¡À» °áÇÕÇÑ ÇÏÀ̺긮µå ½ºÅÙÆ®µµ µîÀåÇß½À´Ï´Ù. ¶ÇÇÑ, °¨¿°°ú ¿°ÁõÀ» ¿¹¹æÇÏ´Â ¾à¹°À» õõÈ÷ ¹æÃâÇÏ´Â ¾à¹° ¿ëÃâ ½ºÅÙÆ®¿Í °°Àº ±â¼ú Çõ½ÅÀ¸·Î ½Ã¼ú ÈÄ ÇÕº´ÁõÀÌ Å©°Ô °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. ¿µ»ó ¹× ³»ºñ°ÔÀÌ¼Ç ±â¼ú ¶ÇÇÑ ½ºÅÙÆ® »ðÀÔÀÇ Á¤È®µµ¸¦ Çâ»ó½ÃÄÑ ½ºÅÙÆ® À̵¿ ¹× ¿À¹èÄ¡ À§ÇèÀ» °¨¼Ò½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ½ºÅÙÆ® ½Ã¼ú ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±ÇÏ´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.

±âµµ/Æó ½ºÅÙÆ® ¼ö¿ä Áõ°¡ÀÇ ¿øµ¿·ÂÀº?

COPD, Æó¾Ï, õ½Ä µî È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡ µî ¿©·¯ ¿äÀÎÀ¸·Î ÀÎÇØ ±âµµ ½ºÅÙÆ®¿¡ ´ëÇÑ ¼¼°è ¼ö¿ä°¡ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ´ë±â¿À¿°, Èí¿¬, °í·ÉÈ­ µîÀÌ ÀÌ·¯ÇÑ ÁúȯÀÇ ±ÞÁõ¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, ÁßȯÀÚ Ä¡·á¿¡¼­ ±âµµ ½ºÅÙÆ®ÀÇ »ç¿ëÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ±âµµ Æó¼â¸¦ °ü¸®Çϱâ À§ÇÑ ÃÖ¼Òħ½ÀÀû ´ë¾ÈÀ¸·Î¼­ ±âµµ ½ºÅÙÆ®ÀÇ È¿°ú¿¡ ´ëÇÑ ÀνÄÀÌ ÀÇ·á Àü¹®°¡¿Í ȯÀÚµé »çÀÌ¿¡¼­ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ½ºÅÙÆ® »ðÀÔ¼úÀº ÀÀ±Þ »óȲ»Ó¸¸ ¾Æ´Ï¶ó ¸»±â ȯÀÚÀÇ Àå±âÀûÀÎ ¿ÏÈ­ Ä¡·á¿¡µµ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù.

±âµµ/Æó ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

±âµµ/Æó ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀº ½ºÅÙÆ® Àç·á ¹× µðÀÚÀÎÀÇ ¹ßÀü, ¸¸¼º È£Èí±âÁúȯÀÇ À¯º´·ü Áõ°¡, ÃÖ¼Òħ½ÀÀû Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ±âÀÎÇÕ´Ï´Ù. ¾à¹° ¿ëÃâ ½ºÅÙÆ® ¹× ¿µ»ó Áø´Ü ±â¼ú Çâ»ó°ú °°Àº ±â¼ú Çõ½ÅÀº Ä¡·á ¼º°ú¿Í ȯÀÚ ¾ÈÀü¼ºÀ» Çâ»ó½ÃÄÑ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, COPD ¹× Æó¾Ï ¹ßº´·üÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ƯÈ÷ °í·ÉÈ­ »çȸ¿Í ´ë±â ¿À¿°ÀÌ ½ÉÇÑ Áö¿ª¿¡¼­ ±âµµ ½ºÅÙÆ®¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °³¹ßµµ»ó±¹ÀÇ ÀÇ·á Á¢±Ù¼º Çâ»óÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ Áß¿äÇÑ ÀåÄ¡ÀÇ Ã¤ÅÃÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ºÎ¹®

Àç·á À¯Çü(±Ý¼Ó, ½Ç¸®ÄÜ, ÇÏÀ̺긮µå), Á¦Ç° À¯Çü(ÀÚ°¡È®ÀåÇü, dz¼±È®ÀåÇü, ºñÈ®ÀåÇü), À¯Çü(±â°ü, ÈĵÎ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Airway/Lung Stents Market to Reach US$163.8 Million by 2030

The global market for Airway/Lung Stents estimated at US$119.3 Million in the year 2024, is expected to reach US$163.8 Million by 2030, growing at a CAGR of 5.4% over the analysis period 2024-2030. Tracheal, one of the segments analyzed in the report, is expected to record a 5.6% CAGR and reach US$96.6 Million by the end of the analysis period. Growth in the Laryngeal segment is estimated at 5.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$32.8 Million While China is Forecast to Grow at 5.1% CAGR

The Airway/Lung Stents market in the U.S. is estimated at US$32.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$25.6 Million by the year 2030 trailing a CAGR of 5.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.1% and 4.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Airway/Lung Stents Market - Key Trends & Drivers Summarized

What Are Airway/Lung Stents and Why Are They Essential for Respiratory Care?

Airway or lung stents are vital medical devices designed to maintain open passages in the respiratory tract, particularly in patients with conditions like chronic obstructive pulmonary disease (COPD), lung cancer, or tracheobronchial obstructions. These stents, made from materials like metal or silicone, are used to prevent airway collapse, helping patients breathe more easily and improving their overall quality of life. Airway stents are especially important for individuals who are not suitable candidates for surgery or where conventional treatments like medications are insufficient to manage severe respiratory obstructions. As the incidence of respiratory diseases continues to rise globally, the role of airway stents in patient care becomes even more critical.

How Are Technological Innovations Revolutionizing Airway Stent Design?

Technological advancements have significantly improved the design and functionality of airway/lung stents. Traditional silicone stents, valued for their removability and flexibility, are now complemented by metal stents, which offer superior durability and long-term structural support. More recently, hybrid stents have emerged, combining the benefits of both materials. Additionally, innovations such as drug-eluting stents, which slowly release medication to prevent infections or inflammation, have greatly reduced post-procedural complications. Imaging and navigation technologies have also improved the precision of stent placement, reducing the risk of stent migration or misplacement. These advancements are driving improved outcomes in patients undergoing stent placement.

What Is Driving the Increased Demand for Airway/Lung Stents?

The global demand for airway stents is steadily increasing due to several factors, including the rising prevalence of respiratory diseases such as COPD, lung cancer, and asthma. Air pollution, smoking, and aging populations have contributed to a surge in these conditions, necessitating the use of airway stents in critical care. Additionally, there is growing awareness among healthcare professionals and patients about the effectiveness of airway stents as a minimally invasive option to manage airway obstruction. This has led to the adoption of stenting procedures not only in emergency situations but also in long-term palliative care for patients with terminal illnesses.

What Factors Are Driving Growth in the Airway/Lung Stents Market?

The growth in the airway/lung stents market is driven by several factors, including advancements in stent materials and designs, the increasing prevalence of chronic respiratory diseases, and the growing demand for minimally invasive treatments. Technological innovations such as drug-eluting stents and improved imaging techniques are enhancing treatment outcomes and patient safety, contributing to market growth. The rising incidence of COPD and lung cancer, particularly in aging populations and regions with high air pollution, is increasing the need for airway stents. Additionally, improved access to healthcare in developing regions is expanding the adoption of these critical devices.

SCOPE OF STUDY:

The report analyzes the Airway/Lung Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Material Type (Metal, Silicone, Hybrid); Product (Self-Expandable, Balloon-Expandable, Non-Expandable); Type (Tracheal, Laryngeal)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â